Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall ...

Pharmaceutical giant Eli Lilly (LLY) has reported second-quarter financial results that beat Wall Street estimates and raised ...

Lilly’s results from an obesity pill study didn’t perform as well as Wall Street expected. It resulted in lower weight loss ...

Results from a late-stage trial of Eli Lilly's experimental weight-loss pill were disappointing, sending shares of the drugmaker tumbling.

Eli Lilly, a renowned drug manufacturer, stated that its GLP-1 pill, orforglipron, assisted individuals in reducing 12.4% of their weight following 72 weeks in a late-stage study.The company ...

Cancer vaccine experts are worried that if the Trump administration takes a hostile posture towards mRNA broadly, cancer ...

At Shifa hospital in the Gaza Strip, nothing is sterilized, so Dr. Jamal Salha and other surgeons wash their instruments in ...

Eli Lilly shares fell as disappointing data on its new weight-loss pill overshadowed strong growth from the company’s current obesity medicine, which helped drive it to raise its yearly profit and ...

Eli Lilly shares plunged 12% in morning trading Thursday after reporting less-than-stellar results of a new study of an experimental anti-obesity pill that is expected to become a blockbuster.The pill ...

Study participants lost an average of 12.4 per cent of their body weight over 72 weeks. View on euronews ...

Live Updates Live Coverage Updates appear automatically as they are published. Discovery-ing Some Profits 9:40 am Continuing ...

A trial assessing a new daily pill for weight loss has shown that people taking the drug can shed kilos in weeks, potentially ...